Article Text

PDF
Letter
Vedolizumab safety in pregnancy and newborn outcomes
  1. Mette Julsgaard1,
  2. Jens Kjeldsen2,
  3. Daniel C Baumgart3
  1. 1 Department of Gastroenterology and Hepatology, Aarhus University Hospital, Aarhus C, Denmark
  2. 2 Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark
  3. 3 Department of Gastroenterology and Hepatology, Charité Medical School, Humboldt-University of Berlin, Berlin, Germany
  1. Correspondence to Professor Daniel C Baumgart, Inflammatory Bowel Disease Center, Charité Medical Center, Virchow Hospital, Medical School of the Humboldt University, Berlin D-13344, Germany; daniel.baumgart{at}charite.de

Statistics from Altmetric.com

We read with interest the study by Colombel et al 1 on vedolizumab (VDZ) safety in Crohn's disease (CD) and ulcerative colitis (UC). These data were derived from pivotal clinical trials which naturally exclude pregnant women, leaving this important area of pharmacovigilance unaddressed. Epidemiologically, the first age peak of IBD frequently overlaps with family planning. Thus, there is considerable interest among couples and healthcare providers on how VDZ impacts on pregnant women and newborns. Here we report the first four fully VDZ exposed and documented pregnancies and newborns.

VDZ (MLN0002, MLN02, LDP-02, anti-α4β7) is a humanised monoclonal IgG1 antibody targeting α4β7 integrin. IgG1 is the predominant means of fetal immunity and maternal–fetal transport across the placenta, which increases linearly throughout pregnancy.2 Therefore, it can …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.